Does gosatuzumab (Todavi) have a high cure rate? How effective is it in patients with different conditions?

Gosatuzumab (Trodelvy) is an antibody-drug conjugate (ADC), mainly used to treat relapsed or refractory metastatic triple-negative breast cancer (TNBC) and urothelial carcinoma (UC) that progressed after platinum-based chemotherapy. Currently, the drug is not considered to have the ability to completely cure cancer, but rather prolongs patients' survival and improves their quality of life by inhibiting the growth of tumor cells. According to clinical trial data, the objective response rate (ORR) of TNBC patients is around **30%-35%** and the overall survival period has been prolonged, but the possibility of complete cure is low.

Gosatuzumab has shown good efficacy in patients with advanced or metastatic triple-negative breast cancer. Clinical studies have shown that the drug can significantly extend the patient's progression-free survival (PFS) to 5-6 months, while the overall survival (OS) can reach about 12 months, which has obvious advantages over traditional chemotherapy regimens. Especially for TNBC patients who have failed at least two lines of treatment, gosatuzumab provides a new treatment option, and some patients can achieve long-term remission.

Gosatuzumab is also indicated for the treatment of locally advanced or metastatic urothelial carcinoma that has failed platinum-based chemotherapy andPD-1/PD-L1 immunotherapy. Studies have shown that the objective response rate (ORR) of this drug is 27%-30%, and some patients can obtain longer-term remission. In this patient population, gosatuzumab extends progression-free survival to approximately 5.4 months and improves overall survival, providing an important survival benefit for some patients.

Although gosatuzumab has shown good efficacy in specific cancer types, its therapeutic effects still vary depending on individual patient differences. For example, patients with lower baseline disease burden, better tolerance of previous treatments, and better performance status tend to have better treatment responses. However, for patients with large tumor burden or multiple drug resistance mechanisms, the efficacy may be limited. In addition, adverse drug reactions, such as bone marrow suppression, nausea, diarrhea, etc., may also affect the treatment compliance of some patients. Therefore, when using gosatuzumab, it is necessary to conduct a comprehensive assessment based on the patient's condition characteristics to optimize the treatment plan.

Reference materials:https://www.trodelvy.com/